Table 4.
Comparison of advanced glycation end product detection techniques in bone tissue and their application limitations
|
Method
|
Minimum sample size
|
Spatial resolution
|
Absolute quantification
|
Major advantages
|
Limitations
|
Ref.
|
| HPLC-FLD/LC-MS | 2 mg defatted bone powder | Yes | High sensitivity; can differentiate CML/CEL/MG-H1/Pen | Destructive; requires acid hydrolysis; labor-intensive | [62] | |
| Autofluorescence (Ex 335/Em 385) | 5 μm tissue section | Micron level | No (relative) | Rapid, high-throughput; suitable for biopsy screening | Interference from mineral/Lipid autofluorescence; cannot distinguish AGE types | [63] |
| Raman spectroscopy | Applicable to both in vivo and tissue sections | Approximately 1 μm | No (semiquantitative) | In situ detection; simultaneously captures mineral-matrix information | Sensitive to water; spectrum interpretation requires expertise | [64] |
| Nano-FTIR/AFM-IR | 10 μm tissue section | 20-50 nm | No (semiquantitative) | Highest spatial resolution; enables single-fiber localization | Expensive equipment; limited scanning area | [65] |
HPLC: High-performance liquid chromatography; FLD: Fluorescence detector; LC-MS: Liquid chromatography-mass spectrometry; Ex: Excitation; Em: Emission; Nano-FTIR: Nanoscale Fourier transform infrared spectroscopy; AFM-IR: Atomic force microscopy-infrared spectroscopy; CML: Nepsilon-(carboxymethyl)lysine; CEL: Nepsilon-(carboxyethyl)lysine; MG-H1: Methylglyoxal-derived hydroimidazolone 1; Pen: Pentosidine; AGE: Advanced glycation end-product.